- Conditions
- Breast Cancer
- Interventions
- Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
- Drug
- Lead sponsor
- Celcuity Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more
Condition Directory
Breast Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 19, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1133
Shown on this page
12
Current sort
Recently updated
Condition scope
Breast Cancer
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Breast Cancer studies are organized in the registry
Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 421–432 of 1,133 matching trials for Breast Cancer.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Breast Cancer Female
- Interventions
- SABR
- Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Breast Cancer, Early-Onset
- Interventions
- Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
- Conditions
- Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
- Interventions
- CAdVEC
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Everolimus, TRC105
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer
- Interventions
- HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Anastrozole, Letrozole, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 20
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- Intrinsic Subtyping of Primary Breast Cancer
- Device
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Raleigh, North Carolina
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy, Discussion, Survey Administration
- Procedure · Device · Drug + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
- Interventions
- Abemaciclib, Niraparib Tosylate Monohydrate
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Lasofoxifene, Fulvestrant
- Drug
- Lead sponsor
- Sermonix Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Yuma, Arizona • Duarte, California + 36 more
About this Breast Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Breast Cancer.